Immuneering Corporation
Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer
Inclusion Criteria: * Aged 18 years or older * Nnon-squamous NSCLC, stage IIIB or stage IV, with no prior systemic treatment for recurrent or metastatic disease. Prior adjuvant or neoadjuvant platinum therapy is allowed if completed more than 6 months before recurrence. * Measurable disease (at least 1 target lesion) per RECIST 1.1. * ECOG performance status of 0 or 1. * PD-L1 score determined by an FDA-approved test. * RAS-mutated NSCLC documented by next-generation sequencing (NGS), performed locally per institutional standards. Results must be available before enrollment. Liquid biopsy is…
Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg
Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks
AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4
500 mg/m² IV on Day 1 of Cycles 1-4
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.